Eye injection shows promise for rare eye cancer
NCT ID NCT07402876
First seen Feb 13, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tests an eye injection of ADX-2191 (a form of methotrexate) to treat primary vitreoretinal lymphoma, a rare eye cancer. About 20 adults with confirmed disease will receive different dosing schedules to see which clears cancer cells from the eye more safely. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VITREORETINAL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bascom Palmer Eye Institute
RECRUITINGMiami, Florida, 33101, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.